EHA2021 CML Oral Sessions

 

Oral Sessions

On demand from 11 June 2021, 09:00 AM CET.

eha logo3

 

Population based studies in myeloid disorders.

  • P411-1 (S155) THE LOSS OF LIFE EXPECTANCY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018. Msc Carolien Maas, The Netherlands.

  • P411-2 (S156) ELTROMBOPAG FOR MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA WITH NO EXCESS BLASTS AND THROMBOCYTOPENIA: A FRENCH MULTICENTER RETROSPECTIVE REAL-LIFE STUDY. Dr. Thibault Comont, France.

  • P411-4 (S158) IMPACT OF RUXOLITINIB ON SURVIVAL OF PATIENTS WITH MYELOFIBROSIS IN REAL WORLD – UPDATE OF ERNEST (EUROPEAN REGISTRY FOR MYELOPROLIFERATIVE NEOPLASMS) STUDY. Dr. Paola Guglielmelli, Italy.

  • P411-5 (S159) CLONAL HEMATOPOIESIS, ELEVATED BLOOD CELL COUNTS, AND DECREASED RENAL FUNCTION – A GENERAL POPULATION STUDY. Msc Morten Kranker Larsen, Denmark.

Live Q&A Panel Discussion. 16 June 2021 1:00 PM - 1:45 PM CET. Virtual room 2.

 

Response, resistance and treatment-free remission in CML

  • p410-1 (S150) LOSS OF G0/G1 SWITCH GENE 2 (G0S2) IN CML PROMOTES TKI RESISTANCE BY DEREGULATING THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN. Mayra Gonzalez, United States.
  • p410-2 (S151) MITOCHONDRIAL DNA MUTATIONS ARE ASSOCIATED WITH RESPONSE TO IMATINIB IN CHRONIC MYELOID LEUKAEMIA PATIENTS. Dr. Ilaria Stefania Pagani, Australia.
  • p410-3 (S152) FINAL ANALYSIS OF A PAN EUROPEAN STOP TYROSINE KINASE INHIBITOR TRIAL IN CHRONIC MYELOID LEUKEMIA : THE EURO-SKI STUDY. Prof. Dr. Susanne Saussele, Germany.
  • p410-4 (S153) OPTIC PRIMARY ANALYSIS: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (PON). Dr. Jorge Cortes, United States.
  • p410-5 (S154) COVID-19 INFECTION IN CHRONIC MYELOID LEUKEMIA AFTER 1 YEAR OF THE PANDEMIC IN ITALY. A CAMPUS CML ANALYSIS. Dr. Massimo Breccia, Italy.

Live Q&A Panel Discussion. 16 June 2021 2:00 PM - 2:45 PM CET. Virtual room 2.

  

 

Please donate!

Please donate!

LogIn

EU e-Privacy Directive